Natera : Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use

(marketscreener.com) FoundationOne®Tracker provides physicians and researchers with a tissue-informed and personalized solution to monitor advanced cancer patients' response to treatment, and help optimize future treatment decisions and therapy development Cambridge, Mass., & Austin, Texas, January 9, 2023 - Foundation Medicine, Inc., a...https://www.marketscreener.com/quote/stock/NATERA-INC-22762534/news/Natera-Foundation-Medicine-and-Natera-Announce-the-Launch-of-FoundationOne-Tracker-Personalized-Ci-42691720/?utm_medium=RSS&utm_content=20230109